Sweden's Q-linea Q3 sales rise; signs new US healthcare agreement

Overview

• Sweden infection diagnostics firm's Q3 net sales grew yr/yr, but contracted instrument sales declined

• Operating loss for Q3 narrowed compared to last year

• Company signed US healthcare agreement and Premier, Inc. framework deal, but US adoption remains slow

Outlook

• Company expects evaluation timelines to decrease as more real-world data is generated

• Company anticipates further deployments in Europe later this year following positive evaluations

• Q-linea expects to announce further product and menu expansions within 6-12 months

Result Drivers

• US MARKET CONTRACTS - Co signed new US healthcare agreement and expanded with existing IDN customer in Q3

• GROUP PURCHASING DEAL - National framework agreement with Premier, Inc. expected to reduce contracting timelines and increase visibility

• CONSUMABLES USAGE - US consumables usage reached highest level in Q3 after expanded menu adoption

Company press release:

Key Details

Reuters Recommended Reads

• Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

• Oct 28 - Sweden's Fenix Outdoor Q3 sales rise on Nordic demand, Devold portfolio addition

• Oct 29 - Sweden's Nolato Q3 profit slips on higher input costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)